Aclaris Therapeutics (ACRS) – Trading Halts
-
Aclaris Therapeutics (ACRS) Phase 2b Trial of Oral Zunsemetinib (ATI-450) Did Not Meet Primary or Secondary Efficacy Endpoints in Rheumatoid Arthritis
-
Aclaris Therapeutics (ACRS) Halted, News Pending
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to ACRS Stock Lookup